Press Releases

Date Title
1/2/19 Sarepta Therapeutics Enters into Long-term Strategic Relationship with Aldevron for GMP-grade Plasmid in Support of Gene Therapy Development and Commercial Manufacturing Strategy
1/2/19 Sarepta Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
12/31/18 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/20/18 Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Golodirsen (SRP-4053) in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53
12/11/18 Sarepta Therapeutics Appoints Mary Ann Gray, Ph.D., to its Board of Directors
11/30/18 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/8/18 Sarepta Therapeutics Announces Pricing of $500,000,000 Public Offering of Common Stock
11/7/18 Sarepta Therapeutics Announces Proposed $500,000,000 Public Offering of Common Stock
11/2/18 Sarepta Therapeutics to Present at Credit Suisse 27th Annual Healthcare Conference
10/31/18 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Displaying 61 - 70 of 620